Close this search box.
Close this search box.

Rapid, Direct-from-Blood Diagnostics that Enable Changes in Clinical Decisions

Industry & Science Showcase during ASM Microbe 2019

This presentation, Rapid, Direct-from-Blood Diagnostics that Enable Changes in Clinical Decisionstook place on Friday, June 21 during ASM Microbe 2019.

The presentation highlighted clinical updates regarding current and future applications of T2 technology, including:

T2Bacteria® provides actionable clinical information

New T2Bacteria Panel clinical data being generated by independent commercial users shows its ability to benefit tested patients in the emergency department by providing information that leads to more rapid time to delivery of effective therapy, de-escalation of unnecessary therapy, and helping avoid premature discharge and readmission to the emergency department.

Meta-analysis of 70 studies highlights significant challenges of empiric therapy (without T2Bacteria and T2Candida®)

46.5% of patients are on inappropriate antibiotic therapy with empiric therapy alone, while >90% are on effective therapy after accurate species identification, such as provided by T2Bacteria and T2Candida.

T2Bacteria clinical patient selection algorithms demonstrate significant clinical impact

Dr. Lowery will review T2Bacteria patient selection algorithms implemented by T2Bacteria customers and summarize emerging clinical utility data of 120 clinical cases demonstrating significant clinical impact. He will also detail multiple cases demonstrating the impact and potential impact of T2Bacteria on clinical outcomes.

T2Resistance™ Panel provides ≥ two-day time advantage compared to conventional methods

The T2Resistance Panel, which was recently granted Breakthrough Device designation by the FDA, is designed to detect 13 resistance genes from both gram-positive and gram-negative pathogens direct from blood. Initial data demonstrates T2Resistance identifies these resistance genes with an average time of 5.3 hours compared to an average of 30 hours (and up to 95 hours) with conventional methods. The T2Resistance Panel is expected to be available for research use only (RUO) in the U.S. and receive CE-Mark for commercial availability in Europe by the end of 2019.

T2MR® Technology has the potential to provide coverage for ≥99% of bloodstream infections

Dr. Lowery will present feasibility data demonstrating that the T2MR Technology has the capability to potentially detect >250 pathogen species, which would cover ≥99% of blood-borne pathogens responsible for bloodstream infections and sepsis. It has also demonstrated the ability to potentially detect resistance markers for all blood-borne antibiotic resistance threats identified by the Centers for Disease Control (CDC). These diagnostic capabilities could allow the Company to develop a panel that provides comprehensive coverage of bloodstream infections.

Please note there was audio corruption upon recording this Showcase.